<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03623256</url>
  </required_header>
  <id_info>
    <org_study_id>1238162</org_study_id>
    <nct_id>NCT03623256</nct_id>
  </id_info>
  <brief_title>Comparison of Intrathecal Versus Epidural Fentanyl on Fetal Bradycardia in Labor Combined Spinal Epidural Analgesia</brief_title>
  <official_title>Comparison of Intrathecal Versus Epidural Fentanyl: Effect of Neuraxial Route of Administration on Fetal Bradycardia in Labor Combined Spinal Epidural Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There have been studies reporting that combined spinal-epidural (CSE) with fentanyl and
      bupivacaine produce fetal bradycardia, (M.Kuczkowski, 2004) (Abr√£o K, 2009 ). It is unknown
      whether any differences in risk exist between fentanyl and bupivacaine when used as a part of
      the CSE procedure. Some authors have reported cases of parturients who developed uterine
      hyperactivity and fetal bradycardia after subarachnoid administration of fentanyl during
      labor. (D'Angelo &amp; Eisenach, 1997) (Friedlander JD, 1997). It has been suggested that uterine
      hypertonus, leading to non-reassuring fetal heart rate tracings, might be an etiologic factor
      in these situations. (Landau, 2002).

      We propose this study to test the hypothesis that administration of epidural fentanyl is
      associated with a lower incidence of fetal bradycardia compared to intrathecal fentanyl.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After approval by the Institutional Review Board and written informed consent, we plan to
      prospectively study pregnant patients who undergo neuraxial labor analgesia. All patients
      will receive combined-spinal-epidural analgesia. Patients will be randomly assigned to one of
      four groups by means of sealed envelope technique. Group A will receive a spinal dose of
      preservative-free fentanyl 25 mcg. Group B will receive one dose of spinal preservative-free
      0.25% bupivacaine. Group C will receive a spinal combination of preservative-free 0.25%
      bupivacaine and fentanyl 25 mcg. Group D will receive spinal preservative-free 0.25%
      bupivacaine and epidural fentanyl 100 mcg. After the procedure, we will monitor the fetal
      heart rate and tocometry tracings for 20 min. Thereafter, an epidural infusion with a
      solution containing 0.125% bupivacaine and 2mcg/mL of fentanyl will be started. We will
      record demographic variables (age, and BMI), obstetric variables (parity, gestational age,
      cervical dilation, oxytocin infusion) and anesthetic variables (level of insertion of
      epidural catheter).

      Primary outcomes:

      Fetal heart rate (baseline, minimal and abnormal patterns)

      Secondary outcomes:

        -  Blood pressure (systolic, diastolic and mean) measured at baseline and every 5 minutes
           after administration of medication.

        -  Dermatomal level measured after 20 minutes of medication administration.

        -  Pain level (visual analogue scale) after 20 minutes of medication administration.

        -  Patient satisfaction level (1-10 scale) after 20 minutes of medication administration.

        -  Uterine tone measured with tocometer at baseline and during 20 minutes after medication
           administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly assigned to one of four groups:
Group A: Spinal dose of preservative-free fentanyl 25 mcg. Group B: Spinal preservative-free 0.25% bupivacaine. Group C: Spinal combination of preservative-free 0.25% bupivacaine and fentanyl 25 mcg.
Group D: Spinal preservative-free 0.25% bupivacaine and epidural fentanyl 100 mcg.
After the procedure, we will monitor the fetal heart rate and tocometry tracings for 30 min. Thereafter, an epidural infusion with a solution containing 0.125% bupivacaine and 2mcg/mL of fentanyl will be started. We will record demographic variables (age, and BMI), obstetric variables (parity, gestational age, cervical dilation, oxytocin infusion) and anesthetic variables (level of insertion of epidural catheter). We will also record level of insertion, blood pressure every 5 minutes, dermatomal level, pain level, patient satisfaction level and pruritus.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant will be blinded. The investigators will not be blinded because they are the same care providers. In addition, the volume of intrathecal anesthetic is different when bupivacaine plus fentanyl is used in comparison with only one medication used.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal heart rate</measure>
    <time_frame>20 minutes (Starting from placement of labor neuraxial block)</time_frame>
    <description>Fetal bradycardia and abnormal fetal heart rate tracing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>20 minutes (Starting from placement of labor neuraxial block)</time_frame>
    <description>Maternal systolic, diastolic and mean arterial pressure measured at baseline and every 5 minutes after administration of medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatomal level</measure>
    <time_frame>20 minutes (Starting from placement of labor neuraxial block)</time_frame>
    <description>Analgesic level measured by sensitivity to temperature stimulus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Pain level: visual analogue scale</measure>
    <time_frame>20 minutes (Starting from placement of labor neuraxial block)</time_frame>
    <description>Pain evaluated by visual analogue scale (0, no pain; 10, worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction level: Likert Scale</measure>
    <time_frame>20 minutes (Starting from placement of labor neuraxial block)</time_frame>
    <description>Satisfaction level measured by Likert Scale (5: fully satisfied, 4: satisfied, 3: neutral, 2: dissatisfied, 1: fully dissatisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine tone</measure>
    <time_frame>20 minutes (Starting from placement of labor neuraxial block)</time_frame>
    <description>Measured with tocometer (In milimeters above baseline) at baseline and during 20 minutes after medication administration.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">558</enrollment>
  <condition>Labor Pain</condition>
  <condition>Obstetric Pain</condition>
  <arm_group>
    <arm_group_label>Spinal Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spinal dose of preservative-free fentanyl 25 mcg (Volume 0.5 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinal Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spinal dose of preservative-free 0.25% bupivacaine (Volume 0.5 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinal Fentanyl and Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spinal combination of preservative-free 0.25% bupivacaine (0.5 mL) and fentanyl 25 mcg (0.5 mL). (Total Volume 1 mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epidural fentanyl /spinal bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spinal preservative-free 0.25% bupivacaine (Volume 0.5 mL) and epidural fentanyl 100 mcg (Volume 2 mL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spinal fentanyl</intervention_name>
    <description>25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.</description>
    <arm_group_label>Spinal Fentanyl</arm_group_label>
    <other_name>Fentora</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spinal bupivacaine</intervention_name>
    <description>1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.</description>
    <arm_group_label>Spinal Bupivacaine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spinal Fentanyl and Bupivacaine</intervention_name>
    <description>1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.</description>
    <arm_group_label>Spinal Fentanyl and Bupivacaine</arm_group_label>
    <other_name>Marcaine and Fentora</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epidural fentanyl /spinal bupivacaine</intervention_name>
    <description>1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.</description>
    <arm_group_label>Epidural fentanyl /spinal bupivacaine</arm_group_label>
    <other_name>Marcaine and Fentora</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years

          -  Term pregnancy (&gt; 37 weeks)

          -  Absence of obstetric morbidities

          -  Active labor

          -  Request of neuraxial analgesia per patient and/or obstetrician

          -  Combined spinal-epidural technique

        Exclusion Criteria:

          -  Abnormal fetal heart rate tracing.

          -  Uterine tachysystole before neuraxial analgesia.

          -  Baseline blood pressure &lt;90/60 mmHg.

          -  Allergies to local anesthetics or fentanyl.

          -  Maternal fever.

          -  Pruritus before performance of neuraxial analgesia.

          -  Contraindications for neuraxial technique.

          -  Unwillingness to participate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant patients in labor</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Efrain Riveros Perez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Efrain Riveros Perez, MD</last_name>
    <phone>7067217361</phone>
    <email>eriverosperez@augusta.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander R Rocuts Martinez, MD</last_name>
    <phone>3304074681</phone>
    <email>krocutsmartinez@augusta.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Meiler, MD</last_name>
      <phone>706-721-3671</phone>
      <email>smeiler@augusta.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Efrain Riveros Perez, MD</investigator_full_name>
    <investigator_title>Assistant Professor Department of Anesthesiology and Perioperative Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The study team will decide about sharing information upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

